OrbiMed Advisors LLC 13-F
제약-바이오 섹터/13-F
2020. 8. 15. 15:07
반응형
반응형
13-F가 줄줄이 나온 기념으로 바이오텍 위주로 투자하는 헷지펀드들의 포트폴리오 변경을 시간나는대로 살펴보기로. 지난 2분기는 바이오 주가가 훨훨 날던 시기. 과연 2분기에 헷지펀드들은 뭘 담고 뭘 팔았을지?
첫빠따로는 OrbiMed Advisors LLC의 2분기 포트폴리오.
| 시장 가치 변화 | $5.95B → $7.103B (+19.4%) |
| 보유 종목수 | 168 |
| 신규 매수 종목수 | 25 |
| 추가 매수 종목수 | 29 |
| 전량 매도 종목수 | 32 |
| 부분 매도 종목수 | 28 |
| Top 10 비중 | 31.14% |
| Top 20 보유 기간 | 4.95 쿼터 |
| Top 10 보유 기간 | 6.10 쿼터 |
| 보유 기간 | 8.30 쿼터 |
포트폴리오 전체의 93%가 헬스케어. 2019년 4분기부터 Other가 늘고 있는데 뭐지? 근데 whalewisdom에서 해놓은 섹터 구분 못믿겠음. Trillium therapeutics inc가 소재로, Arrowhead pharmaceuticals inc가 산업으로 구분되는 등 엉뚱한 분류가 눈에 띔. 보유 종목들 일일히 살펴보면 SPY를 제외하면 나머지는 100% 헬스케어 같음.
아래는 보유 상위 10종목, 비중 확대 종목, 비중 축소 종목들. 그냥 나열해 놓았으니 알아서 보시길.
Top 10 holdings
Springworks와 Tricidia는 들어보기는 했는데.. 좀 살펴봐야겠음.
| 순위 | 이름 | 심볼 | 비중 | 전분기 비중 | % 변화 | 지분율 | 첫보유 | 평균단가 |
| 1 | Springworks therapeutics inc | SWTX | 4.43% | 3.36% | 0.00% | 17.22% | Q3 2019 | $21.68 |
| 2 | Tricida inc | TCDA | 3.76% | 3.55% | 0.00% | 19.25% | Q2 2018 | $30.09 |
| 3 | Alexion pharmaceuticals inc. | ALXN | 3.44% | 3.13% | 4.08% | 0.98% | Q1 2011 | $126.73 |
| 4 | Ascendis pharma a/s adr | ASND | 3.29% | 6.22% | (52.46%) | 2.94% | Q1 2015 | $29.06 |
| 5 | Prevail therapeutics inc | PRVL | 2.93% | 2.83% | 0.00% | 40.41% | Q2 2019 | $13.20 |
| 6 | Merck & co | MRK | 2.85% | 3.35% | 0.00% | 0.10% | Q1 2016 | $63.47 |
| 7 | Vertex pharmaceuticals inc. | VRTX | 2.75% | 2.95% | (9.67%) | 0.26% | Q4 2012 | $96.21 |
| 8 | Biogen inc | BIIB | 2.73% | 2.55% | 49.02% | 0.45% | Q3 2010 | $295.28 |
| 9 | Passage bio inc. | PASG | 2.71% | 1.84% | 0.00% | 15.35% | Q1 2020 | $15.75 |
| 10 | Iovance biotherapeutics inc | IOVA | 2.60% | 2.79% | 19.77% | 4.54% | Q1 2015 | $11.68 |
비중 확대 – 신규 매수
최근 상장한 종목들이 많이 눈에 들어옴. PRTX, ORIC, KROS, FUSN, SLQT, PCVX 등등등 아주 많음. 2분기에 바이오텍 상장이 불을 뿜었던걸 생각하면 당연한 듯. 시리즈 펀딩 단계에서 들어갔을 수도 있고, 개미들은 접근 불가인 공모가에 들어갔을 수도 있고.
타입 컬럼은 옵션. 매수인지 매도인지는 불분명.
| 순위 | 이름 | 심볼 | 타입 | 비중 | 지분율 | 첫보유 | 평균단가 |
| 12 | Boston scientific inc. | BSX | 2.42% | 0.34% | Q2 2020 | $35.11 | |
| 19 | Burning rock biotech ltd. ads | BNR | 1.82% | 4.66% | Q2 2020 | $27.01 | |
| 21 | Repare therapeutics inc. | RPTX | 1.51% | 9.34% | Q2 2020 | $31.02 | |
| 22 | Oric pharmaceuticals inc. | ORIC | 1.40% | 9.77% | Q2 2020 | $33.73 | |
| 33 | Keros therapeutics inc. | KROS | 0.90% | 8.34% | Q2 2020 | $37.51 | |
| 39 | Fusion pharmaceuticals inc | FUSN | 0.80% | N/A | Q2 2020 | $17.47 | |
| 62 | Selectquote inc. | SLQT | 0.45% | 0.78% | Q2 2020 | $25.33 | |
| 66 | Vaxcyte inc. | PCVX | 0.38% | N/A | Q2 2020 | $31.61 | |
| 67 | Immunomedics inc. | IMMU | 0.38% | 0.33% | Q2 2020 | $35.44 | |
| 70 | Teva pharmaceutical industries ltd adr | TEVA | 0.34% | 0.18% | Q2 2020 | $12.33 | |
| 80 | Pandion therapeutics holdco llc | PAND | 0.27% | N/A | |||
| 88 | 9 meters biopharma inc | INNT | 0.21% | 18.88% | Q2 2020 | $0.57 | |
| 89 | Forte biosciences inc. (tocagen) | TOCA | 0.20% | N/A | Q2 2020 | $14.58 | |
| 94 | Fluidigm corp | FLDM | 0.17% | 4.11% | Q2 2020 | $4.01 | |
| 95 | Alexion pharmaceuticals inc. | ALXN | CALL | 0.16% | N/A | Q2 2020 | |
| 96 | Arcturus therapeutics ltd | ARCT | 0.16% | 1.17% | Q2 2020 | $46.74 | |
| 98 | Genmark diagnostics inc | GNMK | 0.15% | 1.04% | Q2 2020 | $14.71 | |
| 101 | Abbvie inc | ABBV | CALL | 0.14% | N/A | Q2 2020 | |
| 105 | Progyny inc. | PGNY | 0.13% | 0.40% | Q2 2020 | $25.81 | |
| 110 | Celldex therapeutics inc. | CLDX | 0.12% | 1.61% | Q2 2020 | $13.00 | |
| 111 | Rocket pharmaceuticals inc | RCKT | 0.11% | 0.69% | Q2 2020 | $20.93 | |
| 112 | Akouos inc | AKUS | 0.10% | N/A | Q2 2020 | $22.50 | |
| 118 | Avidity biosciences inc. | RNA | 0.08% | N/A | Q2 2020 | $28.26 | |
| 119 | Arcus biosciences inc | RCUS | 0.08% | 0.42% | Q2 2020 | $24.74 | |
| 122 | Calliditas therapeutics ab ads | CALT | 0.07% | N/A | Q2 2020 | $23.20 | |
| 129 | Corbus pharmaceuticals holdings inc | CRBP | PUT | 0.04% | N/A | Q2 2020 |
비중 확대 – 추가 매수
여기있는 종목들은 대략 알만한 종목들.
| 순위 | 이름 | 심볼 | 비중 | 전분기 비중 | % 변화 | 지분율 | 첫보유 | 평균단가 |
| 3 | Alexion pharmaceuticals inc. | ALXN | 3.44% | 3.13% | 4.08% | 0.98% | Q1 2011 | $126.73 |
| 8 | Biogen inc | BIIB | 2.73% | 2.55% | 49.02% | 0.45% | Q3 2010 | $295.28 |
| 10 | Iovance biotherapeutics inc | IOVA | 2.60% | 2.79% | 19.77% | 4.54% | Q1 2015 | $11.68 |
| 13 | Bristol-myers squibb co | BMY | 2.41% | 2.32% | 16.46% | 0.13% | Q2 2007 | $61.16 |
| 15 | Horizon therapeutics plc | HZNP | 2.27% | 1.17% | 22.47% | 1.46% | Q4 2019 | $38.01 |
| 17 | Neurocrine biosciences inc. | NBIX | 2.06% | 1.68% | 2.68% | 1.28% | Q1 2012 | $86.24 |
| 23 | Agios pharmaceuticals inc | AGIO | 1.32% | 0.99% | 4.58% | 2.51% | Q1 2020 | $36.27 |
| 40 | Atricure inc | ATRC | 0.79% | 0.52% | 32.32% | 3.06% | Q4 2019 | $36.22 |
| 43 | Theravance biopharma inc | TBPH | 0.76% | 0.08% | 1107.53% | 4.05% | Q1 2020 | $21.17 |
| 45 | Crispr therapeutics ag | CRSP | 0.73% | 0.39% | 26.55% | 1.02% | Q3 2019 | $52.94 |
| 46 | Crinetics pharmaceuticals inc | CRNX | 0.69% | 0.50% | 35.03% | 8.38% | Q3 2018 | $25.60 |
| 48 | Meiragtx holdings plc | MGTX | 0.66% | 0.81% | 3.67% | 9.94% | Q3 2018 | $16.39 |
| 49 | Abbvie inc | ABBV | 0.65% | 0.29% | 102.62% | 0.03% | Q1 2020 | $87.33 |
| 50 | Mersana therapeutics inc | MRSN | 0.64% | 0.13% | 41.83% | 2.80% | Q1 2019 | $10.64 |
| 54 | Alpine immune sciences inc | ALPN | 0.56% | 0.50% | 3.96% | 20.53% | ||
| 56 | Aeglea biotherapeutics inc | AGLE | 0.53% | 0.22% | 40.13% | 9.00% | Q2 2016 | $7.60 |
| 57 | Prothena corp plc | PRTA | 0.53% | 0.52% | 22.13% | 8.88% | Q1 2019 | $11.56 |
| 59 | Scpharmaceuticals inc | SCPH | 0.50% | 0.42% | 40.68% | 17.91% | Q4 2017 | $10.72 |
| 63 | Xenon pharmaceuticals inc | XENE | 0.45% | 0.32% | 50.22% | 7.14% | Q3 2016 | $10.92 |
| 71 | Flexion therapeutics inc | FLXN | 0.32% | 0.02% | 1166.17% | 4.37% | Q2 2019 | $13.75 |
| 79 | Regeneron pharmaceuticals inc. | REGN | 0.27% | 0.14% | 79.65% | 0.03% | Q1 2011 | $475.73 |
| 83 | Iveric bio inc | ISEE | 0.24% | 0.04% | 333.33% | 3.67% | Q4 2019 | $5.90 |
| 85 | Syndax pharmaceuticals inc | SNDX | 0.23% | 0.05% | 277.28% | 3.03% | Q1 2016 | $14.25 |
| 90 | Avrobio inc | AVRO | 0.20% | 0.17% | 19.68% | 2.20% | Q2 2018 | $17.13 |
| 93 | Larimar therapeutics inc | LRMR | 0.17% | 0.01% | 913.26% | N/A | Q4 2019 | $12.16 |
| 102 | Trillium therapeutics inc | TRIL | 0.14% | 0.05% | 51.19% | 1.43% | Q1 2020 | $5.41 |
| 103 | Heron therapeutics inc | HRTX | 0.14% | 0.11% | 22.89% | 0.73% | Q1 2020 | $12.29 |
| 106 | Immunovant ord shs | IMVT | 0.12% | 0.05% | 97.53% | N/A | Q1 2020 | |
| 108 | Xtant med hldgs inc com (de) | XTNT | 0.12% | 0.10% | 0.45% | N/A | Q1 2018 | |
| 114 | Aptose biosciences inc | APTO | 0.09% | 0.07% | 44.29% | 1.25% | Q4 2019 | $5.87 |
비중 축소 – 부분 매도
많이 올라서 판 종목도 보이고, 폭망해서 판 종목도 보이고...
| 순위 | 이름 | 심볼 | 타입 | 비중 | 전분기 비중 | % 변화 | 지분율 | 첫보유 | 평균단가 |
| 4 | Ascendis pharma a/s adr | ASND | 3.29% | 6.22% | (52.46%) | 2.94% | Q1 2015 | $29.06 | |
| 7 | Vertex pharmaceuticals inc. | VRTX | 2.75% | 2.95% | (9.67%) | 0.26% | Q4 2012 | $96.21 | |
| 14 | Natera inc | NTRA | 2.30% | 1.68% | (3.18%) | 4.12% | Q3 2015 | $25.05 | |
| 16 | Mirati therapeutics inc | MRTX | 2.15% | 1.84% | (6.97%) | 3.03% | Q3 2019 | $106.68 | |
| 24 | Dexcom inc | DXCM | 1.31% | 1.53% | (33.02%) | 0.24% | Q4 2018 | $178.60 | |
| 25 | Sarepta therapeutics inc | SRPT | 1.28% | 1.48% | (37.99%) | 0.72% | Q4 2017 | $117.76 | |
| 29 | Avalanche biotechnologies inc | ADVM | 0.98% | 0.57% | (4.63%) | 4.10% | Q1 2019 | $6.91 | |
| 30 | Deciphera pharmaceuticals inc | DCPH | 0.96% | 0.80% | (2.76%) | 2.02% | Q3 2017 | $24.10 | |
| 31 | 89bio inc. | ETNB | 0.92% | 1.12% | (50.00%) | 11.88% | |||
| 32 | Intuitive surgical inc | ISRG | 0.91% | 1.41% | (33.29%) | 0.10% | Q4 2013 | $377.90 | |
| 35 | Alector inc | ALEC | 0.87% | (50.47%) | 3.45% | ||||
| 37 | Exelixis inc | EXEL | 0.81% | 0.92% | (24.40%) | 0.78% | Q2 2018 | $20.39 | |
| 44 | Bellus health ord shs | BLU | 0.75% | 1.17% | (26.88%) | N/A | Q3 2019 | ||
| 47 | Glaukos corp | GKOS | 0.66% | 0.80% | (21.75%) | 2.74% | Q4 2019 | $54.47 | |
| 51 | Applied therapeutics inc | APLT | 0.63% | 0.73% | (7.74%) | 5.50% | Q4 2019 | $28.64 | |
| 52 | Uniqure n.v. | QURE | 0.62% | 0.78% | (1.51%) | 2.19% | Q2 2019 | $76.70 | |
| 64 | Harpoon therapeutics inc | HARP | 0.43% | 0.48% | (24.96%) | 7.34% | Q1 2019 | $9.47 | |
| 74 | Amgen inc. | AMGN | 0.31% | 0.36% | (13.02%) | 0.02% | Q4 2002 | $132.68 | |
| 78 | Aurinia pharmaceuticals inc | AUPH | 0.28% | 0.33% | (10.49%) | 1.06% | Q1 2019 | $6.51 | |
| 87 | Gilead sciences inc. | GILD | 0.21% | 1.85% | (86.93%) | 0.02% | Q2 2006 | $73.48 | |
| 92 | Acceleron pharma inc | XLRN | 0.17% | 0.39% | (50.49%) | 0.21% | Q4 2019 | $74.49 | |
| 115 | Selecta biosciences inc | SELB | 0.08% | 0.11% | (19.28%) | 2.39% | Q2 2016 | $8.74 | |
| 120 | Agios pharmaceuticals inc | AGIO | CALL | 0.08% | 0.15% | (60.00%) | N/A | Q1 2020 | |
| 123 | Arena pharmaceuticals inc | ARNA | 0.06% | 0.09% | (50.00%) | 0.12% | Q2 2019 | $55.71 | |
| 127 | Inflarx nv | IFRX | 0.04% | 0.07% | (36.44%) | 2.58% | Q1 2020 | $3.82 | |
| 130 | Intellia therapeutics inc | NTLA | 0.04% | 0.05% | (47.69%) | 0.23% | Q2 2016 | $21.35 | |
| 131 | Curis inc | CRIS | 0.02% | 0.02% | (8.60%) | 3.39% | Q3 2019 | $2.19 | |
| 134 | Menlo therapeutics inc | MNLO | 0.01% | 0.08% | (66.09%) | 0.35% | Q3 2018 | $2.68 | |
| 135 | Arvinas holding company llc | ARVN | 0.01% | 0.67% | (97.05%) | 0.08% | Q3 2018 | $16.82 |
비중 축소 – 전량 매도
Pfenex를 파셨네...
| 순위 | 이름 | 심볼 | 타입 | 비중 | 전분기 비중 | % 변화 | 지분율 | 첫보유 | 평균단가 |
| 168 | Boston scientific corp. 5.5% mandatory convertible preferred stock series a due 6/1/2023 | BSX+A | 0.00% | 2.66% | (100.00%) | N/A | Q4 2019 | ||
| 138 | Pfizer inc. | PFE | 0.00% | 1.65% | (100.00%) | 0.00% | Q1 2020 | $32.64 | |
| 145 | Hca healthcare inc | HCA | 0.00% | 1.07% | (100.00%) | 0.00% | Q4 2019 | $105.36 | |
| 139 | Stryker corp. | SYK | 0.00% | 1.04% | (100.00%) | 0.00% | Q1 2020 | $166.49 | |
| 146 | Ptc therapeutics inc | PTCT | 0.00% | 0.86% | (100.00%) | 0.00% | Q3 2018 | $44.97 | |
| 140 | Biomarin pharmaceutical inc | BMRN | 0.00% | 0.77% | (100.00%) | 0.00% | Q2 2015 | $84.50 | |
| 142 | Bausch health companies | BHC | 0.00% | 0.63% | (100.00%) | 0.00% | Q3 2018 | $22.37 | |
| 137 | Pfizer inc. | PFE | CALL | 0.00% | 0.27% | (100.00%) | N/A | Q1 2020 | |
| 141 | Spdr s&p 500 etf trust | SPY | PUT | 0.00% | 0.27% | (100.00%) | No Data | Q1 2020 | |
| 159 | Zai lab ltd | ZLAB | 0.00% | 0.22% | (100.00%) | 0.00% | Q3 2017 | $24.35 | |
| 150 | Pfenex inc | PFNX | 0.00% | 0.19% | (100.00%) | 0.00% | Q4 2019 | $9.84 | |
| 166 | Neoleukin therapeutics ord shs | NLTX | 0.00% | 0.18% | (100.00%) | N/A | Q4 2019 | ||
| 143 | Spdr s&p health care etf | XLV | 0.00% | 0.17% | (100.00%) | No Data | Q4 2019 | $101.86 | |
| 144 | Spdr s&p biotech etf | XBI | 0.00% | 0.17% | (100.00%) | No Data | Q4 2019 | $95.11 | |
| 155 | Regenxbio inc | RGNX | 0.00% | 0.15% | (100.00%) | 0.00% | Q4 2019 | $33.24 | |
| 147 | Cara therapeutics inc | CARA | 0.00% | 0.13% | (100.00%) | 0.00% | Q1 2020 | $13.21 | |
| 153 | Adaptimmune therapeutics plc adr | ADAP | 0.00% | 0.12% | (100.00%) | 0.00% | Q2 2015 | $4.93 | |
| 167 | Revolution medicines inc. | RVMD | 0.00% | 0.11% | (100.00%) | 0.00% | Q1 2020 | $21.91 | |
| 157 | Argenx se ads adr | ARGX | 0.00% | 0.06% | (100.00%) | 0.00% | Q2 2017 | $38.81 | |
| 152 | Kalvista pharmaceuticals inc | KALV | 0.00% | 0.05% | (100.00%) | 0.00% | Q1 2019 | $10.96 | |
| 165 | Neubase therapeutics ord shs | NBSE | 0.00% | 0.04% | (100.00%) | N/A | Q1 2020 | ||
| 162 | Aptinyx inc | APTX | 0.00% | 0.04% | (100.00%) | 0.00% | Q4 2019 | $2.32 | |
| 161 | Bioxcel therapeutics inc | BTAI | 0.00% | 0.04% | (100.00%) | 0.00% | Q1 2020 | $22.35 | |
| 148 | Agile therapeutics inc | AGRX | 0.00% | 0.04% | (100.00%) | 0.00% | Q1 2020 | $1.86 | |
| 164 | Cassava sciences inc | SAVA | CALL | 0.00% | 0.03% | (100.00%) | N/A | Q1 2020 | |
| 160 | Apellis pharmaceuticals inc | APLS | 0.00% | 0.02% | (100.00%) | 0.00% | Q4 2018 | $26.79 | |
| 163 | Sutro biopharma inc | STRO | 0.00% | 0.02% | (100.00%) | 0.00% | Q4 2019 | $11.00 | |
| 149 | Intersect ent inc | XENT | 0.00% | 0.01% | (100.00%) | 0.00% | Q1 2020 | $11.85 | |
| 158 | Mustang bio inc | MBIO | 0.00% | 0.01% | (100.00%) | 0.00% | Q4 2019 | $4.08 | |
| 156 | Protagonist therapeutics inc | PTGX | 0.00% | 0.01% | (100.00%) | 0.00% | Q4 2019 | $7.05 | |
| 154 | Catabasis pharmaceuticals inc | CATB | 0.00% | 0.00% | (100.00%) | 0.00% | Q1 2020 | $4.15 | |
| 151 | Otonomy inc | OTIC | 0.00% | 0.00% | (100.00%) | 0.00% | Q4 2019 | $3.83 |
반응형
'제약-바이오 섹터 > 13-F' 카테고리의 다른 글
| 11개 유명 바이오 펀드 4분기 13F 종합 분석 (0) | 2022.02.17 |
|---|---|
| [13-F] Avoro Capital Advisors LLC (formerly venBio) 2분기 포트폴리오 변화 (5) | 2020.09.15 |
| [13-F] Perceptive Advisors LLC 2분기 포트폴리오 변화 (4) | 2020.08.21 |
| [13-F] 2분기에 Baker Bros는 뭘 팔고 뭘 샀을까? (10) | 2020.08.18 |